Leo Cancer Care, a medical technology company designing imaging and treatment systems around the body's natural upright position, has raised £50 million in an oversubscribed Series D financing led by Yu Galaxy, with new investor Eventide Asset Management and continued support from existing investors.
The platform is built on the idea that because the human body spends most of its life upright, Leo designs imaging and treatment around that natural position; growing research indicates this may support more consistent anatomical positioning and organ stability compared with conventional supine treatments. At the heart of the platform is an FDA-cleared upright imaging system, with planned future applications across radiology in addition to its role in treatment planning and delivery. On the treatment side, Leo's Marie platform fixes the radiation beam and gently rotates the seated patient rather than a multi-tonne gantry, enabling a proton therapy treatment room around five times smaller than a conventional gantry-based system and allowing proton therapy to be installed within existing radiotherapy vaults. The upright, eye-level position also keeps patients in conversation and eye contact with their clinical team throughout treatment rather than lying flat beneath a machine, and Leo's StatueQuest gamified educational platform aims to reduce or eliminate the need for daily sedation for children.
The financing will scale manufacturing, accelerate commercial deployment, and support continued clinical and product development across Leo Cancer Care's integrated upright platform. Alongside the financing, the company has entered a major strategic partnership with an international healthcare giant, with further details of the collaboration to be announced separately in the coming weeks.
What began as a vision to improve radiation therapy has evolved into something much broader. For decades, the industry has tried to lower the cost of cancer care by making equipment cheaper and stripping out capability. Our treatment approach is the opposite - to reimagine how care is delivered, designed around the patient rather than the machine, so advanced treatment can reach communities that never had access before, without compromising quality. This financing lets us accelerate that platform strategy across proton, photon and imaging.
Leo Cancer Care is poised to revolutionize cancer treatment in more than ten countries, with many installations the first in their region or country. The upright radiotherapy and radiology technologies Leo has pioneered are lowering the cost and shortening the time of cancer treatment, and providing options that did not exist before for pediatric patients and patients of larger body size. The result is a dramatic expansion of access to both radiotherapy and diagnostic radiology for a far larger population.
